Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 4/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31491061 | 0.87 | EGLN2 (0.35) | LCKALDH1A1NPC1TP53RAB9A | |
| SCHEMBL30776330 | 0.80 | LCK (0.37) | LCKATRMAPKAPK2ALDH1A1NPC1 | |
| SCHEMBL26530970 | 0.80 | LCK (0.37) | LCKATRMAPKAPK2ALDH1A1NPC1 | |
| SCHEMBL31085630 | 0.79 | LCK (0.35) | LCKATRMAPKAPK2ALDH1A1NPC1 | |
| SCHEMBL30587220 | 0.79 | ATR (0.35) | LCKATRMAPKAPK2ALDH1A1NPC1 | |
| SCHEMBL26119259 | 0.79 | ATR (0.35) | LCKATRMAPKAPK2ALDH1A1NPC1 | |
| SCHEMBL25643117 | 0.75 | ALDH1A1 (0.38) | ALDH1A1NPC1TP53MAPTHSD17B10 | |
| SCHEMBL31470308 | 0.75 | CA1 (0.34) | LCKALDH1A1NPC1RAB9AEGLN2 | |
| SCHEMBL24717559 | 0.75 | ALDH1A1 (0.36) | LCKALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL31085770 | 0.74 | EGLN2 (0.35) | LCKATRMAPKAPK2SYKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| WO-2024206766-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LCK 601/4885ATR 945/4885STK17B 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.